Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers

Farhat, Ghada N.; Cummings, Steven R.; Chlebowski, Rowan T.; Parimi, Neeta; Cauley, Jane A.; Rohan, Thomas E.; Huang, Alison J.; Vitolins, Mara Z.; Hubbell, F. Allan; Manson, JoAnn E.; Cochrane, Barbara B.; Lane, Dorothy S.; Lee, Jennifer S.

doi:10.1093/jnci/djr031

Cited by 93 publications

(79 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the majority of men with breast cancer have no identifiable risk factor, several have been identified with an imbalance in estrogen, excess or lack of androgen (chronic liver diseases, cryptorchidism and Klinefelter’s syndrome). Farhat et al [19], in a prospective study of healthy postmenopausal women who were not taking hormone therapy, observed that higher serum estradiol levels were associated with an increased risk of ER-positive breast cancer, although there is no information available in men. However, Callari et al [20] reported a different pattern of gene expression of steroid receptors in MBC specimens compared to samples of ER-positive FBC with similar clinical and pathological features, indicating that there may be many differences between the biology of MBC and FBC.…”

Section: Discussionmentioning

confidence: 99%

Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

Sánchez-Muñoz¹,

Román-Jobacho

Pérez-Villa

et al. 2012

Oncology

View full text Add to dashboard Cite

Aim: The aim of this study was to assess the molecular subtype profiles of male breast cancer (MBC) and subsequent clinical outcome using a validated 6-marker immunohistochemical panel. Methods: A total of 43 cases of MBC were examined retrospectively using a semiquantitative immunohistochemical analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (Her2), epidermal growth factor receptor and cytokeratin 5/6. Patients were classified into the following categories: luminal A, luminal B, Her2-positive or basal-like subtypes. Results: The median age of patients was 63 years (r: 32–89). The predominant histology was invasive ductal carcinoma (91%). Only 1 patient had advanced breast cancer at diagnosis. Ninety-three percent were ER-positive and 84% were PR-positive. Two patients had tumors that were ER- and PR-negative. The distribution of tumor molecular subtypes was 19 (44%) luminal A, 22 (51%) luminal B and 2 (5%) basal-like. The Her2-positive tumor subtype was not identified. The clinicopathological characteristics did not differ significantly between tumor subtypes A and B. There were no significant differences in 6-year disease-free survival (74 vs. 82%, p = 0.77) or overall survival (74 vs. 82%, p = 0.69) between luminal A and luminal B subtypes, respectively. Conclusion: The most common subtypes in our cohort of MBC were luminal B followed by luminal A, and no differences were found between both tumor subtypes in terms of clinicopathologic characteristics and patient outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

Sánchez-Muñoz¹,

Román-Jobacho

Pérez-Villa

et al. 2012

Oncology

View full text Add to dashboard Cite

show abstract

“…Initial studies that investigated ER-negative breast cancers included only 20-45 women with little power to show any significant association (12,15,17,27,28). More recently there have been two larger studies by James et al (13), who investigated 172 ER-negative breast cancers and by Fharat et al (14), who investigated 111 ER-negatives breast cancers, which have shown conflicting results. The first study reported serum androgens (testosterone and free testosterone) and estrogens (estradiol and free estradiol) to be associated with increased risks of both ER-positive and ER-negative breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…The majority of such studies have explored overall breast cancer (8,10,11) or ER-positive breast cancer risk (9,12). There are only five studies that have reported the association by hormone receptor status (13)(14)(15)(16)(17). They are characterised by relatively small numbers and conflicting results.…”

Section: Introductionmentioning

confidence: 99%

Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS)

et al. 2016

View full text Add to dashboard Cite

show abstract

“…So, multicenter, double-blind, placebo-controlled, phase II clinical trial of Panagen in female patients with stage II-IV breast cancer displayed leukostimulatory and leukoprotective effects during chemotherapy [21]. The development and progression of breast cancer in human are under sex hormones control [8,10,22]. In thorax duct lymph of prolactin was decreased in animal after chemotherapy, whereas additional administration exogenous DNA possessed to save it on the levels as in control group of animals.…”

Section: International Journal Of Pharmacology Phytochemistry and Etmentioning

confidence: 99%

Feature of Experimental Breast Cancer Induced by Intermammary Administration of N-Methyl-N-Nitrosourea in Wistar Rat

Лыков

Kabakov

Kazakov

et al. 2017

IJPPE

View full text Add to dashboard Cite

Abstract. Breast cancer is the leading cause of cancer death in women worldwide due to the complicated etiology involving both genetic and environmental factors. BC was induced by N-Methyl-N-Nitrosourea administration intermammary in Wistar female. Studied frequency of development of NMU-induced BC, phenotype of BC cells, phenotype of MSC from mammary gland tissue, quantity and quality of immunocompetent cells, expression of miRNAs, hormone levels and cytokines were done for estimate sensitivity to chemotherapy.We showed that MNU-induced BC developed in 90%, immunohistochemical similar to human luminal A type of BC with higher proliferation activity. We estimated significantly increased count of BC-MSC with CD45+CD90-, and CD45+CD90+, and CD45-CD90+ phenotype in animal with MNU-induced BC. Chemotherapy caused changes in quality and quantity of immunocompetent cells, decrease of prolactin and luteinizing hormone levels, and some changes in expression of pro-oncogenic or tumor-suppressing miRNAs. In MNU-induced BC animal were observed increased serum levels of pro-inflammatory cytokines. In regional lymph nodes found increased count of macrophages and presence of tumor cells. Intermammary administration of NMU possessed to breast cancer development with similarities to human luminal B phenotype. This MNU-induced breast cancer may serve as a model to study efficiency of chemotherapy.

show abstract

Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers

Abstract: Higher serum levels of bioavailable testosterone are associated with lower risks of ER-negative breast cancer in postmenopausal women.

Cited by 93 publications

References 29 publications

Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS)

Feature of Experimental Breast Cancer Induced by Intermammary Administration of N-Methyl-N-Nitrosourea in Wistar Rat

Contact Info

Product

Resources

About